These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Suppression of murine tumour growth through CD8 Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313 [TBL] [Abstract][Full Text] [Related]
3. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905 [TBL] [Abstract][Full Text] [Related]
4. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605 [TBL] [Abstract][Full Text] [Related]
5. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist. Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment. Carnevalli LS; Ghadially H; Barry ST Front Immunol; 2021; 12():633685. PubMed ID: 33953710 [TBL] [Abstract][Full Text] [Related]
7. Treg-mediated acquired resistance to immune checkpoint inhibitors. Saleh R; Elkord E Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738 [TBL] [Abstract][Full Text] [Related]
8. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG Front Immunol; 2020; 11():620166. PubMed ID: 33584714 [TBL] [Abstract][Full Text] [Related]
9. Enhanced suppression of polyclonal CD8 Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300 [TBL] [Abstract][Full Text] [Related]
10. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy. Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991 [No Abstract] [Full Text] [Related]
11. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma. Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966 [TBL] [Abstract][Full Text] [Related]
13. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267 [TBL] [Abstract][Full Text] [Related]
14. Differentiation and Regulation of T Basu A; Ramamoorthi G; Albert G; Gallen C; Beyer A; Snyder C; Koski G; Disis ML; Czerniecki BJ; Kodumudi K Front Immunol; 2021; 12():669474. PubMed ID: 34012451 [TBL] [Abstract][Full Text] [Related]
15. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors. Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902 [TBL] [Abstract][Full Text] [Related]
16. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8 Yin W; Song Y; Liu Q; Wu Y; He R Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970 [TBL] [Abstract][Full Text] [Related]
17. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer. Li TJ; Wang WQ; Yu XJ; Liu L Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188384. PubMed ID: 32531324 [TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes. Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813 [TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F Front Immunol; 2018; 9():14. PubMed ID: 29403496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]